Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.

Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM.

J Infect Dis. 1999 Apr;179(4):799-807.

2.

Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.

Lange CG, Lederman MM, Madero JS, Medvik K, Asaad R, Pacheko C, Carranza C, Valdez H.

J Acquir Immune Defic Syndr. 2002 May 1;30(1):33-40.

PMID:
12048361
4.

Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.

Plana M, García F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barceló JJ, Vidal C, Cruceta A, Miró JM, Gatell JM.

AIDS. 2000 Sep 8;14(13):1921-33.

PMID:
10997396
6.

Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection.

Orendi JM, Bloem AC, Borleffs JC, Wijnholds FJ, de Vos NM, Nottet HS, Visser MR, Snippe H, Verhoef J, Boucher CA.

J Infect Dis. 1998 Nov;178(5):1279-87.

7.

HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.

Lubaki NM, Shepherd ME, Brookmeyer RS, Hon H, Quinn TC, Kashamuka M, Johnson M, Gottle R, Devers J, Lederman HM, Bollinger RC.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):19-30.

PMID:
10534143
9.

Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.

Larsen CS, Ostergård L, Møller BK, Buhl MR.

Scand J Infect Dis. 2000;32(2):153-60.

PMID:
10826900
10.

CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.

Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):332-40.

PMID:
9704938
11.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
12.

Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.

Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.

Antivir Ther. 1997 Jul;2(3):175-83.

PMID:
11322272
13.

Limited immune reconstitution at intermediate stages of HIV-1 infection during one year of highly active antiretroviral therapy in antiretroviral-naive versus non-naive adults.

Martín M, Echevarría S, Leyva-Cobián F, Pereda I, López-Hoyos M.

Eur J Clin Microbiol Infect Dis. 2001 Dec;20(12):871-9.

PMID:
11837638
14.

Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.

Benito JM, López M, Lozano S, Ballesteros C, Martinez P, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):373-81.

PMID:
15764953
15.

Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.

Beran O, Holub M, Spála J, Kalanin J, Stanková M.

Acta Virol. 2003;47(2):121-4.

PMID:
14524479
16.

'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses.

Lederman MM, Kalish LA, Asmuth D, Fiebig E, Mileno M, Busch MP.

AIDS. 2000 May 26;14(8):951-8.

PMID:
10853976
17.

Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, Wolinsky SM, Detels R.

J Infect Dis. 1999 Apr;179(4):859-70.

20.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, Pumarola T, Gallart T, Miró JM, Gatell JM.

AIDS. 1999 Jul 30;13(11):F79-86.

PMID:
10449278
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk